HOME >> BIOLOGY >> NEWS
Highlights from the October Journal of the American Dietetic Asociation

The October 2005 issue of the Journal of the American Dietetic Association contains articles and research studies you may find of interest. Below is a summary of one of this month's articles. For more information or to receive a faxed copy of a Journal article, e-mail media@eatright.org.

Soy Consumption among Women at Risk for Breast Cancer

Researchers at Fox Chase Cancer Center in Pennsylvania studied the eating patterns of more than 450 women who are at increased risk of breast cancer to quantify and qualify use of soy products in the women's diets. Research is attempting to find whether soy has a role in the prevention or treatment of chronic diseases, including breast cancer, but results to date are inconclusive.

The women in the Pennsylvania study each had family histories of breast cancer and were enrolled in a cancer risk assessment program. Findings from the study include:

  • 32 percent of the women described themselves as "soy consumers" and 43 percent said they eat at least one soy product per month.
  • Of the women identified as soy consumers, more than 70 percent gave "I try to eat a healthy diet" as a reason. "I like the taste" was cited by nearly 60 percent and nearly half said "I believe they will reduce my cancer risk."
  • Soy foods most commonly eaten include vegetable burgers, tofu and soy milk.
  • Among women who said they did not eat soy foods, the two most popular reasons were "I don't know how to prepare or cook them" and "I dislike their taste." Other reasons included "I don't believe they are healthier for me than other foods" and "They are difficult to find."

The researchers conclude that "a subset of women may be consuming soy for misguided reasons or nonproven health benefits. It is important for health professionals to deliver clear messages about the health benefits, if any, of soy."


'"/>

Contact: Kelly Liebbe
media@eatright.org
American Dietetic Association
1-Oct-2005


Page: 1

Related biology news :

1. Highlights from the July 2007 Journal of the American Dietetic Association
2. AGU Journal Highlights -- April 16, 2007
3. Highlights from the April 2007 Journal of the American Dietetic Association
4. Highlights from the January 2007 Journal of the American Dietetic Association
5. Highlights from the December 2006 Journal of the American Dietetic Association
6. Highlights from the November 2006 Journal of the American Dietetic Association
7. Highlights from the October 2006 Journal of the American Dietetic Association
8. Highlights from the September 2006 Journal of the American Dietetic Association
9. Highlights from the August 2006 Journal of the American Dietetic Association
10. Highlights from the June 2006 Journal of the American Dietetic Association
11. Highlights from the May 2006 Journal of the American Dietetic Association

Post Your Comments:
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:11/21/2014)... YORK , Nov. 19, 2014  Earlier this ... at New York College, and one of the most ... biosensor signals that are transmitted from Smartphones to third ... were Smartphones and has one of the earliest known ... discussing its usage in the military, child care, elder ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
(Date:12/15/2014)... & PETACH TIKVAH, Israel ... (NASDAQ: BCLI ), a leading developer of ... that wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded ... Israel,s Office of the Chief Scientist (OCS).  ... in receipt of grant support from the Office of ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/15/2014)... 15, 2014  Ascendis Pharma A/S, a biotechnology ... address significant unmet medical needs, today announced positive ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... This interim analysis consists of 25 patients, representing ... the study, completing all six months of treatment. ...
(Date:12/13/2014)... - MaRS and Virgin Unite Canada, the non-profit foundation of ... to support Canadian entrepreneurs tackling social and environmental challenges. Today, ... the MaRS Centre to announce the new partnership, which includes ... fund has $1 million in seed capital provided by Virgin ... Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
Cached News: